Johnson & Johnson

Piper Jaffray released its Medical Technology & Hospital Supplies update today after attending the Current Concepts in Joint Replacement meeting (CCJR). In a note to clients, Piper Jaffray writes, "We came away from the CCJR meeting with a mixed bag of feedback regarding the outlook for volume...

Yesterday, Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that it entered into an exclusive agreement with Johnson & Johnson (NYSE: JNJ) to distribute an authorized generic (AG) version of Concerta beginning on May 1, 2011, Piper Jaffray reports. The economics surrounding the agreement will...

The announced agreement for an authorized Concerta generic between Johnson & Johnson (NYSE: JNJ) and Watson Pharmaceuticals, Inc. (NYSE: WPI) brings Concerta generic earlier than anticipated, Piper Jaffray reports. “However, by our analysis, the impact on JNJ's earnings will be relatively...

If we were all as lucky as Warren Buffett, we would be able to make investments in companies like ConocoPhillips (NYSE: COP), U.S. Bancorp (NYSE: USB-PH), Kraft Foods (NYSE: KFT), Sanofi-Aventis (NYSE: SNY), Johnson & Johnson (NYSE: JNJ) and Wells Fargo & Company (NYSE: WFC) and call them...

In leading off the reporting season next week for medical devices Johnson & Johnson (NYSE: JNJ) is positioned to set the tone for Q3 results for many other names in Med Tech and Hospital Supplies, Piper Jaffray reports. “As a large and broadbased provider of devices and supplies for...

Piper Jaffray has published a research report on Medical Technology and Hospital Supplies as sales continue to track above expectations, as witnessed in September earnings results. In the report, Piper Jaffray writes "JNJ: Tracking $24 MM ahead of expectations - Upside in Q3 is being driven...

Auriga USA has published a research report on Affymax, Inc. (NASDAQ: AFFY) following the announcement of its co-ownership of certain intellectual property with Johnson & Johnson (NYSE: JNJ). In the report, Auriga writes "AFFY announced the arbitration panel reviewing its IP dispute with Johnson...

Piper Jaffray prefers stocks that have potential for greater upsides, and has thus remained Neutral on both Alcon, Inc. (NYSE: ACL) and Johnson & Johnson (NYSE: JNJ). In the research report, Piper Jaffray writes "For ACL, the company is benefiting from pricing gains, as well as low single digit...

According to Goldman Sachs, Johnson & Johnson (NYSE: JNJ) was highlighted with risk as it headed into it's 2Q due to $0.11 below consensus rating and potential management guidance reduction for 2010 due to cost-restructuring challenges. Goldman has maintained Johnson & Johnson at "neutral...